Drug intelligence / Profile preview

DMB-3111

Development stage: Phase 1
Lead developer: Meiji Seika Pharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DMB-3111 is a biosimilar of trastuzumab, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2/ERBB2). It is being jointly developed by Meiji Seika Pharma (Japan) and Dong-A Socio Holdings (Korea). Like the reference product trastuzumab, DMB-3111 binds to HER2 receptors on tumor cells and mediates its antitumor effects primarily through antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of HER2 signaling. The drug has demonstrated bioequivalence to trastuzumab in pharmacokinetics, safety, and immunogenicity studies in healthy volunteers. Its primary indications under development are HER2-positive breast cancer and gastric cancer[1][3][4].

Other names: trastuzumab biosimilar

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on DMB-3111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DMB-3111.

Explore the full profile